Grace Records Net Loss Of $7 Mln In FY26; To Resubmit NDA For GTx-104 In Subarachnoid Hemorrhages

Grace Therapeutics reported fiscal year results ended March 31, 2026 and provided an update on its NDA resubmission for GTx-104 in aneurysmal subarachnoid hemorrhage. The announcement is primarily operational and regulatory, with no financial figures or approval decision disclosed in the excerpt. The news is relevant for pipeline progress, but the near-term market impact appears limited absent additional details.

Analysis

Grace Therapeutics reported fiscal year results ended March 31, 2026 and provided an update on its NDA resubmission for GTx-104 in aneurysmal subarachnoid hemorrhage. The announcement is primarily operational and regulatory, with no financial figures or approval decision disclosed in the excerpt. The news is relevant for pipeline progress, but the near-term market impact appears limited absent additional details.